MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · IEX Real-Time Price · USD
4.400
-0.230 (-4.97%)
Jul 19, 2024, 4:00 PM EDT - Market closed

MaxCyte Revenue

MaxCyte had revenue of $44.05M in the twelve months ending March 31, 2024, with 6.80% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $11.34M with 32.25% year-over-year growth. In the year 2023, MaxCyte had annual revenue of $41.29M.

Revenue (ttm)
$44.05M
Revenue Growth
+6.80%
P/S Ratio
10.44
Revenue / Employee
$308,068
Employees
143
Market Cap
459.99M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202341.29M-2.97M-6.72%
Dec 31, 202244.26M10.37M30.59%
Dec 31, 202133.89M7.73M29.52%
Dec 31, 202026.17M4.55M21.04%
Dec 31, 201921.62M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Enhabit 1.04B
Bioventus 522.74M
Pacific Biosciences of California 200.43M
Voyager Therapeutics 119.04M
Theravance Biopharma 61.51M
EyePoint Pharmaceuticals 50.02M
Absci 5.35M
Revenue Rankings